Merck Closes In On Acceleron But BMS And Anti-Trust Regulators Could Be Obstacles

Bidding War May Ensue

 
• By Andrew McConaghie
  
Merck_New_Jersey
Merck & Co has enjoyed huge success with Keytruda, but needs to find ways to reduce its reliance on the blockbuster immunotherapy.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip